MA39155A1 - Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol - Google Patents

Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol

Info

Publication number
MA39155A1
MA39155A1 MA39155A MA39155A MA39155A1 MA 39155 A1 MA39155 A1 MA 39155A1 MA 39155 A MA39155 A MA 39155A MA 39155 A MA39155 A MA 39155A MA 39155 A1 MA39155 A1 MA 39155A1
Authority
MA
Morocco
Prior art keywords
formoterol
combination
glycopyrronium bromide
aerosol solution
hydroxy
Prior art date
Application number
MA39155A
Other languages
English (en)
Inventor
Sauro Bonelli
Diego Copelli
Alberi Massimiliano Dagli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA39155A1 publication Critical patent/MA39155A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007—Mechanical counters
    • A61M15/0071—Mechanical counters having a display or indicator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A61M2039/226—Spindles or actuating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition de solution d'aérosol, conçue pour être utilisée avec un aérosol-doseur mis sous pression, comportant du bromure de glycopyrronium et du formotérol, ou un sel de ceux-ci ou un solvate dudit sel, facultativement en combinaison avec un ou plusieurs principes actifs supplémentaires, stabilisée par une quantité choisie d'un acide minéral, la quantité de produit de dégradation n-(3-bromo)-[2-hydroxy-5-[l-hydroxy-2-[l-(4- méthoxyphényl) propan-2-ylamino]éthyl] phényl] formamide étant inférieure à la limite de quantification, lorsqu'elle est stockée dans des conditions accélérées à 25 °c et à une humidité relative (rh) de 60 % pendant 6 mois dans une boîte recouverte intérieurement par une résine comportant un polymère d'éthylène-propylène fluoré (fep). Le ou les principes actifs facultatifs peuvent être un corticostéroïde d'inhalation choisi parmi le dipropionate de béclométasone, le budésonide ou son épimère 22r, le ciclésonide, le flunisolide, le propionate de fluticasone, le furoate de fluticasone, le furoate de mométasone, etc.
MA39155A 2013-12-30 2016-06-28 Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol MA39155A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199784 2013-12-30
PCT/EP2014/079259 WO2015101576A1 (fr) 2013-12-30 2014-12-23 Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol

Publications (1)

Publication Number Publication Date
MA39155A1 true MA39155A1 (fr) 2017-04-28

Family

ID=49886777

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39155A MA39155A1 (fr) 2013-12-30 2016-06-28 Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol

Country Status (34)

Country Link
US (2) US10596113B2 (fr)
EP (3) EP3384898A1 (fr)
JP (2) JP6563950B2 (fr)
KR (2) KR101861119B1 (fr)
CN (2) CN105848641B (fr)
AR (1) AR098982A1 (fr)
AU (1) AU2014375301B2 (fr)
BR (1) BR112016014583B1 (fr)
CA (1) CA2935305C (fr)
CL (1) CL2016001653A1 (fr)
CY (1) CY1120668T1 (fr)
DK (1) DK3089735T3 (fr)
EA (1) EA033227B1 (fr)
ES (1) ES2687345T3 (fr)
HK (1) HK1225313A1 (fr)
HR (1) HRP20181551T1 (fr)
HU (1) HUE039513T2 (fr)
IL (1) IL246498B (fr)
LT (1) LT3089735T (fr)
MA (1) MA39155A1 (fr)
MX (1) MX368835B (fr)
MY (1) MY182861A (fr)
PE (1) PE20160997A1 (fr)
PH (1) PH12016501268A1 (fr)
PL (1) PL3089735T3 (fr)
PT (1) PT3089735T (fr)
RS (1) RS57687B1 (fr)
SA (1) SA516371427B1 (fr)
SG (1) SG11201605311UA (fr)
SI (1) SI3089735T1 (fr)
TN (1) TN2016000261A1 (fr)
TW (1) TWI660747B (fr)
UA (1) UA117845C2 (fr)
WO (1) WO2015101576A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738712B1 (ko) * 2009-12-23 2017-05-22 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 조합요법
NZ600789A (en) 2009-12-23 2014-09-26 Chiesi Farma Spa Aerosol formulation for copd
RS53391B2 (sr) 2009-12-23 2023-09-29 Chiesi Farm Spa Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
KR101865131B1 (ko) 2013-12-30 2018-06-08 키에시 파르마슈티시 엣스. 피. 에이. 글리코피로니움 브로마이드 및 포모테롤 조합의 안정한 가압 에어로졸 용액 조성물
UA117845C2 (uk) * 2013-12-30 2018-10-10 К'Єзі Фармачеутічі С.П.А. Композиція стійкого аерозольного розчину під тиском комбінації глікопіронію броміду та формотеролу
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
AU2016364650B2 (en) 2015-12-04 2019-04-04 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
ES2892673T3 (es) 2016-09-19 2022-02-04 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
WO2020084549A1 (fr) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Composition de nébulisation comprenant du glycopyrrolate et du formotérol
WO2021009572A1 (fr) * 2019-07-12 2021-01-21 Kindeva Drug Delivery L.P. Formulation d'aérosol, cartouche et inhalateur contenant la formulation, et procédé d'utilisation
BR112022010188A2 (pt) 2019-12-02 2022-08-09 Chiesi Farm Spa Formulação farmacêutica de solução de aerossol, lata de aerossol, inaladores pressurizados de dose calibrada e uso da referida formulação
IL294804A (en) * 2020-01-28 2022-09-01 Chiesi Farm Spa Inhalers with a measured dose under pressure containing the composition of pharmacy buffers
IL295269A (en) * 2020-02-20 2022-10-01 Chiesi Farm Spa Inhalers with a measured dose under pressure that include the composition of pharmacy buffers
BR112023001689A2 (pt) 2020-07-31 2023-05-02 Chemo Res S L Terapia de combinação para administração por inalação
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
WO2022074183A1 (fr) 2020-10-09 2022-04-14 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour inhalateur doseur pressurisé
WO2023117985A1 (fr) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Formulations de poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée
WO2023227782A1 (fr) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour aérosol-doseur pressurisé
WO2023227783A1 (fr) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour aérosol-doseur sous pression
WO2023227781A1 (fr) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour aérosol-doseur sous pression

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
ATE234604T1 (de) 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
BR0015884A (pt) 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
EP1241113A1 (fr) * 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhalateur avec des moyens pour améliorer la stabilité chimique des solutions d'aerosol médicinales qu'il contient
EP1321159A1 (fr) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
SI1718336T1 (sl) 2004-02-06 2008-10-31 Meda Pharma Gmbh & Co Kg Nova kombinacija antiholinergika in beta mimetikov za zdravljenje respiratornih bolezni
SI1713473T1 (sl) 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
CN100457087C (zh) * 2004-02-27 2009-02-04 奇斯药制品公司 用于加压计量吸入器的稳定的药用溶液制剂
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
WO2005112902A2 (fr) * 2004-05-13 2005-12-01 Chiesi Farmaceutici S.P.A. Produits de formulation d'aerosol medicinale a stabilite chimique amelioree
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
MX2007012084A (es) 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP2201934A1 (fr) * 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Produits de formule d'aérosol de tiotropium avec stabilité chimique améliorée
CA2764867C (fr) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Traitement d'une maladie pulmonaire obstructive chronique par administration de beta 2 agoniste nebulise ou d'une combinaison de beta 2 agoniste nebulise et d'anticholinergique
NZ600789A (en) * 2009-12-23 2014-09-26 Chiesi Farma Spa Aerosol formulation for copd
RS53391B2 (sr) 2009-12-23 2023-09-29 Chiesi Farm Spa Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
KR101738712B1 (ko) 2009-12-23 2017-05-22 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 조합요법
EP2515856B1 (fr) 2009-12-23 2014-04-02 Chiesi Farmaceutici S.p.A. Formule d'aérosol pour COPD
CA2808287A1 (fr) 2010-09-06 2012-03-15 Chiesi Farmaceutici S.P.A. Actionneur d'inhalateur-doseur, et inhalateur-doseur correspondant
CN103687483A (zh) * 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
CN104582771B (zh) 2012-08-29 2018-09-04 奇斯药制品公司 气溶胶吸入装置
UA117845C2 (uk) * 2013-12-30 2018-10-10 К'Єзі Фармачеутічі С.П.А. Композиція стійкого аерозольного розчину під тиском комбінації глікопіронію броміду та формотеролу
KR101865131B1 (ko) * 2013-12-30 2018-06-08 키에시 파르마슈티시 엣스. 피. 에이. 글리코피로니움 브로마이드 및 포모테롤 조합의 안정한 가압 에어로졸 용액 조성물

Also Published As

Publication number Publication date
EA033227B1 (ru) 2019-09-30
SA516371427B1 (ar) 2018-12-24
TWI660747B (zh) 2019-06-01
UA117845C2 (uk) 2018-10-10
NZ721642A (en) 2021-02-26
TW201609185A (zh) 2016-03-16
HK1225313A1 (zh) 2017-09-08
JP2017507169A (ja) 2017-03-16
CL2016001653A1 (es) 2017-08-25
PE20160997A1 (es) 2016-10-14
US20150182450A1 (en) 2015-07-02
CN111150728A (zh) 2020-05-15
AU2014375301A1 (en) 2016-07-14
EP3566694A1 (fr) 2019-11-13
CN105848641A (zh) 2016-08-10
KR20180032660A (ko) 2018-03-30
PL3089735T3 (pl) 2018-12-31
AR098982A1 (es) 2016-06-22
TN2016000261A1 (en) 2017-10-06
US20160303045A1 (en) 2016-10-20
ES2687345T3 (es) 2018-10-24
US10617638B2 (en) 2020-04-14
KR20160104041A (ko) 2016-09-02
IL246498B (en) 2020-05-31
LT3089735T (lt) 2018-09-10
CN105848641B (zh) 2021-07-09
EP3384898A1 (fr) 2018-10-10
RS57687B1 (sr) 2018-11-30
SG11201605311UA (en) 2016-07-28
IL246498A0 (en) 2016-08-31
CA2935305C (fr) 2022-07-12
AU2014375301B2 (en) 2020-03-26
JP6823118B2 (ja) 2021-01-27
CA2935305A1 (fr) 2015-07-09
DK3089735T3 (en) 2018-09-17
MX368835B (es) 2019-10-18
EP3089735B1 (fr) 2018-07-11
JP2019206557A (ja) 2019-12-05
PH12016501268B1 (en) 2016-08-15
WO2015101576A1 (fr) 2015-07-09
JP6563950B2 (ja) 2019-08-21
KR101861117B1 (ko) 2018-05-28
PH12016501268A1 (en) 2016-08-15
EP3089735A1 (fr) 2016-11-09
BR112016014583A2 (fr) 2017-08-08
PT3089735T (pt) 2018-10-19
HUE039513T2 (hu) 2019-01-28
BR112016014583B1 (pt) 2022-12-20
KR101861119B1 (ko) 2018-05-28
EA201691126A1 (ru) 2016-12-30
MX2016008594A (es) 2016-09-26
SI3089735T1 (sl) 2018-10-30
MY182861A (en) 2021-02-05
HRP20181551T1 (hr) 2018-11-30
US10596113B2 (en) 2020-03-24
CY1120668T1 (el) 2019-12-11
CN111150728B (zh) 2024-02-06

Similar Documents

Publication Publication Date Title
MA39155A1 (fr) Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol
MA39154A1 (fr) Composition stable pressurisée de solution pour aérosol d'une combinaison de bromure de glycopyrronium et de formotérol
RU2012142295A (ru) Способ приготовления частиц носителя для сухих порошков для ингаляции
HRP20140864T1 (hr) Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergiäśke agoniste
AU2014205529B2 (en) Methods and compositions for treatment of demyelinating diseases
NZ600789A (en) Aerosol formulation for copd
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
RU2018103940A (ru) Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза
JP2016510012A5 (fr)
BR112022014228A2 (pt) Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
EP3937905A4 (fr) Compositions de rinçage et leurs utilisations pour l'administration d'agents actifs
CA3193038A1 (fr) Formulation pharmaceutique pour inhalateur doseur pressurise
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
JP2011500731A5 (fr)
JP2014527056A5 (fr)
TH171992A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
ZA202108150B (en) An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate
TH171993A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
PL432374A1 (pl) Nowy inhalacyjny system terapeutyczny dostarczający zredukowaną ilość propionianu flutikazonu i salmeterolu o zwiększonej skuteczności i profilu bezpieczeństwa
TR201716233A2 (tr) Solunum yolları hastalıklarının tedavisi için birden fazla etken madde içeren farmasötik bileşim.
TR201714893A1 (tr) Beta-2 Agonisti ve Kortikosteroid içeren kuru toz bileşimi.
UA109530C2 (uk) Композиції, способи та системи для доставки респіраторним шляхом двох чи більше активних агентів
TH113758B (th) องค์ประกอบเชิงเภสัชกรรมสำหรับการให้ยาโดยการรับประทาน